The differential expression of P450 in the progression of NAFLD to NASH and/or fibrosis has an important clinical implication in patient treatment to avoid adverse drug reactions and possible drug toxicity. The gene discussed is CYP2B6; the disease is metabolic dysfunction-associated steatohepatitis.